GlassScriptPhysician profile
Wadih Nadour
NPI 1699934620
$8,441.99
in general payments reported to CMS, 2019-2025
38 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $274 · 2021: $560 · 2022: $532 · 2023: $1,917 · 2024: $1,586 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,360 · Consulting Fee: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.05 |
| Consulting Fee | $148.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,001.37 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $880.19 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $593.97 | 2020-2025 | Avvigo Guidance System, Watchman Access System, General - Balloon Catheters |
| Janssen Pharmaceuticals, INC | $516.70 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $415.65 | 2023-2025 | Lifevest |
| Terumo Medical Corporation | $414.79 | 2021-2025 | Tr Band |
| Abbott Laboratories | $391.01 | 2019-2025 | Xact, Nc Trek Neo, Pressurewire |
| Scpharmaceuticals INC. | $389.68 | 2023-2025 | |
| Medtronic Vascular, INC. | $350.71 | 2019 | |
| Shockwave Medical, INC | $325.76 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.45 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $319.44 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $270.92 | 2021-2025 | Farxiga, Wainua |
| Amgen INC. | $244.84 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $231.48 | 2019-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $217.05 | 2023-2025 | Ffrct |
| Pfizer INC. | $214.00 | 2019-2025 | |
| Cardiac Dimensions, INC. | $171.64 | 2024 | |
| Jenavalve Technology, INC. | $148.09 | 2024 | |
| Vifor Pharma, INC. | $116.96 | 2021 | |
| Novo Nordisk INC | $116.72 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $113.35 | 2022-2025 | Corevalve Evolut R |
| Kestra Medical Technology Services, INC. | $88.46 | 2024-2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $85.70 | 2022-2025 | Uptravi, Opsynvi |
| Kiniksa Pharmaceuticals International, Plc | $84.29 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $81.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $59.24 | 2023-2025 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $52.07 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $48.39 | 2023-2024 | Onpattro |
| Inari Medical, INC. | $29.78 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tactile Systems Technology INC | $27.20 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $23.89 | 2023 | Inpefa |
| W. L. Gore & Associates, INC. | $23.80 | 2021 | |
| Amarin Pharma, INC. | $17.57 | 2021 | |
| Irhythm Technologies, INC. | $15.34 | 2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $14.70 | 2023 | Arcalyst |
| Bracco Diagnostics INC. | $14.00 | 2021 | |
| Lantheus Medical Imaging, INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wadih Nadour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.